{"parse":{"title":"Dopamine dysregulation syndrome","pageid":20806653,"revid":840774400,"text":{"*":"<div class=\"mw-parser-output\"><table class=\"infobox\" style=\"width:22em\"><tbody><tr><th colspan=\"2\" style=\"text-align:center;font-size:125%;font-weight:bold;background:#ccc\">Dopamine dysregulation syndrome</th></tr><tr><td colspan=\"2\" style=\"text-align:center\">\n<a href=\"/wiki/File:Dopamine_3D_ball.png\" class=\"image\"><img alt=\"Dopamine 3D ball.png\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/3/36/Dopamine_3D_ball.png/300px-Dopamine_3D_ball.png\" width=\"300\" height=\"208\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/3/36/Dopamine_3D_ball.png/450px-Dopamine_3D_ball.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/3/36/Dopamine_3D_ball.png/600px-Dopamine_3D_ball.png 2x\" data-file-width=\"2000\" data-file-height=\"1386\" /></a></td></tr><tr><td colspan=\"2\" style=\"text-align:center\">\nThree-dimensional model of the structure of a dopamine molecule. Dopamine is at the origin of DDS.</td></tr></tbody></table>\n<p><b>Dopamine dysregulation syndrome</b> (<b>DDS</b>) is a dysfunction of the <a href=\"/wiki/Reward_system\" title=\"Reward system\">reward system</a> observed in some individuals taking dopaminergic medications for an extended length of time. It typically occurs in people with <a href=\"/wiki/Parkinson%27s_disease\" title=\"Parkinson&#39;s disease\">Parkinson's disease</a> (PD) who have taken <a href=\"/wiki/Dopamine_agonist\" title=\"Dopamine agonist\">dopamine agonist</a> medications for an extended period of time. It is characterized by self-control problems such as <a href=\"/wiki/Addiction\" title=\"Addiction\">addiction</a> to medication, <a href=\"/wiki/Problem_gambling\" title=\"Problem gambling\">gambling</a>, or <a href=\"/wiki/Sexual_addiction\" title=\"Sexual addiction\">sexual behavior</a>.<sup id=\"cite_ref-pmid17988927_1-0\" class=\"reference\"><a href=\"#cite_note-pmid17988927-1\">&#91;1&#93;</a></sup>\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Signs_and_symptoms\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Signs and symptoms</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Causes\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Causes</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#Diagnosis\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Diagnosis</span></a></li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#Prevention\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Prevention</span></a></li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#Management\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Management</span></a></li>\n<li class=\"toclevel-1 tocsection-6\"><a href=\"#Epidemiology\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">Epidemiology</span></a></li>\n<li class=\"toclevel-1 tocsection-7\"><a href=\"#History\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">History</span></a></li>\n<li class=\"toclevel-1 tocsection-8\"><a href=\"#Notes\"><span class=\"tocnumber\">8</span> <span class=\"toctext\">Notes</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Signs_and_symptoms\">Signs and symptoms</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Dopamine_dysregulation_syndrome&amp;action=edit&amp;section=1\" title=\"Edit section: Signs and symptoms\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:252px;\"><a href=\"/wiki/File:Punding.jpg\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/f/ff/Punding.jpg/250px-Punding.jpg\" width=\"250\" height=\"133\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/f/ff/Punding.jpg 1.5x\" data-file-width=\"324\" data-file-height=\"173\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:Punding.jpg\" class=\"internal\" title=\"Enlarge\"></a></div><a href=\"/wiki/Punding\" title=\"Punding\">Punding</a>, a possible symptom of DDS, is the repetition of complex motor behaviors such as collecting or arranging objects.</div></div></div>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:252px;\"><a href=\"/wiki/File:Slot_machine.jpg\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/b/bd/Slot_machine.jpg/250px-Slot_machine.jpg\" width=\"250\" height=\"166\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/b/bd/Slot_machine.jpg/375px-Slot_machine.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/bd/Slot_machine.jpg/500px-Slot_machine.jpg 2x\" data-file-width=\"3008\" data-file-height=\"2000\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:Slot_machine.jpg\" class=\"internal\" title=\"Enlarge\"></a></div>A slot machine, commonly used for gambling.</div></div></div>\n<p>The most common symptom is craving for dopaminergic medication. However other behavioral symptoms can appear independently of craving or co-occur with it.<sup id=\"cite_ref-pmid14505581_2-0\" class=\"reference\"><a href=\"#cite_note-pmid14505581-2\">&#91;2&#93;</a></sup> Craving is an intense impulse of the subject to obtain medication even in the absence of symptoms that indicate its intake.<sup id=\"cite_ref-pmid14505581_2-1\" class=\"reference\"><a href=\"#cite_note-pmid14505581-2\">&#91;2&#93;</a></sup> To fulfill this need the person will self-administer extra doses. When self-administration is not possible, aggressive outbursts or the use of strategies such as symptom simulation or bribery to access additional medication can also appear.<sup id=\"cite_ref-pmid14505581_2-2\" class=\"reference\"><a href=\"#cite_note-pmid14505581-2\">&#91;2&#93;</a></sup>\n</p><p><a href=\"/wiki/Hypomania\" title=\"Hypomania\">Hypomania</a>, manifesting with feelings of <a href=\"/wiki/Euphoria_(emotion)\" class=\"mw-redirect\" title=\"Euphoria (emotion)\">euphoria</a>, omnipotence, or grandiosity, are prone to appear in those moments when medication effects are maximum;  <a href=\"/wiki/Dysphoria\" title=\"Dysphoria\">dysphoria</a>, characterized by sadness, psychomotor slowing, <a href=\"/wiki/Fatigue_(medical)\" class=\"mw-redirect\" title=\"Fatigue (medical)\">fatigue</a> or <a href=\"/wiki/Apathy\" title=\"Apathy\">apathy</a> are typical with dopamine replacement therapy (DRT) withdrawal.<sup id=\"cite_ref-pmid14505581_2-3\" class=\"reference\"><a href=\"#cite_note-pmid14505581-2\">&#91;2&#93;</a></sup> Different <a href=\"/wiki/Impulse_control_disorder\" title=\"Impulse control disorder\">impulse control disorders</a> have been described including <a href=\"/wiki/Problem_gambling\" title=\"Problem gambling\">gambling</a>, <a href=\"/wiki/Oniomania\" class=\"mw-redirect\" title=\"Oniomania\">compulsive shopping</a>, <a href=\"/wiki/Eating_disorder\" title=\"Eating disorder\">eating disorders</a> and <a href=\"/wiki/Hypersexuality\" title=\"Hypersexuality\">hypersexuality</a>.<sup id=\"cite_ref-pmid14505581_2-4\" class=\"reference\"><a href=\"#cite_note-pmid14505581-2\">&#91;2&#93;</a></sup> Behavioral disturbances, most commonly <a href=\"/wiki/Aggression\" title=\"Aggression\">aggressive</a> tendencies, are the norm. <a href=\"/wiki/Psychosis\" title=\"Psychosis\">Psychosis</a> is also common.<sup id=\"cite_ref-pmid14505581_2-5\" class=\"reference\"><a href=\"#cite_note-pmid14505581-2\">&#91;2&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Causes\">Causes</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Dopamine_dysregulation_syndrome&amp;action=edit&amp;section=2\" title=\"Edit section: Causes\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Parkinson's disease is a common <a href=\"/wiki/Neurology\" title=\"Neurology\">neurological disorder</a> characterized by a degeneration of dopamine <a href=\"/wiki/Neuron\" title=\"Neuron\">neurons</a> in the <a href=\"/wiki/Substantia_nigra\" title=\"Substantia nigra\">substantia nigra</a> and a loss of dopamine in the <a href=\"/wiki/Putamen\" title=\"Putamen\">putamen</a>. It is described as a motor disease, but it also produces cognitive and behavioral symptoms. The most common treatment is dopamine replacement therapy, which consists in the administration of levodopa (<a href=\"/wiki/L-Dopa\" class=\"mw-redirect\" title=\"L-Dopa\">L-Dopa</a>) or dopamine agonists (such as pramipexole or ropinirole) to patients. Dopamine replacement therapy is well known to improve motor symptoms but its effects in cognitive and behavioral symptoms are more complex.<sup id=\"cite_ref-pmid15935475_3-0\" class=\"reference\"><a href=\"#cite_note-pmid15935475-3\">&#91;3&#93;</a></sup> Dopamine has been related to the normal learning of stimuli with behavioral and motivational significance, <a href=\"/wiki/Attention\" title=\"Attention\">attention</a>, and most importantly the <a href=\"/wiki/Reward_system\" title=\"Reward system\">reward system</a>.<sup id=\"cite_ref-pmid15247533_4-0\" class=\"reference\"><a href=\"#cite_note-pmid15247533-4\">&#91;4&#93;</a></sup> In accordance with the role of dopamine in reward processing, <a href=\"/wiki/Substance_dependence\" title=\"Substance dependence\">addictive</a> <a href=\"/wiki/Drug\" title=\"Drug\">drugs</a> stimulate dopamine release.<sup id=\"cite_ref-pmid15247533_4-1\" class=\"reference\"><a href=\"#cite_note-pmid15247533-4\">&#91;4&#93;</a></sup> Although the exact mechanism has yet to be elucidated, the role of dopamine in the reward system and addiction has been proposed as the origin of DDS.<sup id=\"cite_ref-pmid15247533_4-2\" class=\"reference\"><a href=\"#cite_note-pmid15247533-4\">&#91;4&#93;</a></sup> Models of addiction have been used to explain how dopamine replacement therapy produces DDS.<sup id=\"cite_ref-pmid14505581_2-6\" class=\"reference\"><a href=\"#cite_note-pmid14505581-2\">&#91;2&#93;</a></sup> One of these models of addiction proposes that over the usage course of a drug there is a <a href=\"/wiki/Habituation\" title=\"Habituation\">habituation</a> to the rewarding that it produces at the initial stages. This habituation is thought to be dopamine mediated. With long-term administration of L-dopa the reward system gets used to it and needs higher quantities. As the user increases drug intake there is a loss of dopaminergic receptors in the <a href=\"/wiki/Striatum\" title=\"Striatum\">striatum</a> which acts in addition to an impairment in <a href=\"/wiki/Executive_functions\" title=\"Executive functions\">goal-direction mental functions</a> to produce an enhancement of <a href=\"/wiki/Sensitization\" title=\"Sensitization\">sensitization</a> to dopamine therapy. The behavioral and mood symptoms of the syndrome are produced by the dopamine <a href=\"/wiki/Drug_overdose\" title=\"Drug overdose\">overdose</a>.<sup id=\"cite_ref-pmid15247533_4-3\" class=\"reference\"><a href=\"#cite_note-pmid15247533-4\">&#91;4&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Diagnosis\">Diagnosis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Dopamine_dysregulation_syndrome&amp;action=edit&amp;section=3\" title=\"Edit section: Diagnosis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Diagnosis of the syndrome is clinical since there are no laboratory tests to confirm it. For diagnosis a person with documented responsiveness to medication has to increase medication intake beyond dosage needed to relieve their parkinsonian symptoms in a pathological addiction-like pattern. A current mood disorder (<a href=\"/wiki/Major_depressive_disorder\" title=\"Major depressive disorder\">depression</a>, <a href=\"/wiki/Anxiety\" title=\"Anxiety\">anxiety</a>, hypomanic state or euphoria), behavioral disorder (excessive gambling, shopping or sexual tendency, aggression, or social isolation) or an altered perception about the effect of medication also have to be present.<sup id=\"cite_ref-pmid15390130_5-0\" class=\"reference\"><a href=\"#cite_note-pmid15390130-5\">&#91;5&#93;</a></sup> A <a href=\"/wiki/Questionnaire\" title=\"Questionnaire\">questionnaire</a> on the typical symptoms of DDS has also been developed and can help in the diagnosis process.<sup id=\"cite_ref-pmid14598089_6-0\" class=\"reference\"><a href=\"#cite_note-pmid14598089-6\">&#91;6&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Prevention\">Prevention</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Dopamine_dysregulation_syndrome&amp;action=edit&amp;section=4\" title=\"Edit section: Prevention\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The main prevention measure proposed is the prescription of the lowest possible dose of dopamine replacement therapy to individuals at risk.<sup id=\"cite_ref-pmid15247533_4-4\" class=\"reference\"><a href=\"#cite_note-pmid15247533-4\">&#91;4&#93;</a></sup> The minimization of the use of dopamine agonists, and of short duration formulations of L-Dopa can also decrease risk of the syndrome.<sup id=\"cite_ref-pmid15247533_4-5\" class=\"reference\"><a href=\"#cite_note-pmid15247533-4\">&#91;4&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Management\">Management</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Dopamine_dysregulation_syndrome&amp;action=edit&amp;section=5\" title=\"Edit section: Management\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>First choice management measure consists in the enforcement of a dopaminergic drug dosage reduction. If this decrease is maintained, dysregulation syndrome features soon decrease.<sup id=\"cite_ref-pmid15247533_4-6\" class=\"reference\"><a href=\"#cite_note-pmid15247533-4\">&#91;4&#93;</a></sup> Cessation of <a href=\"/wiki/Dopamine_agonist\" title=\"Dopamine agonist\">dopamine agonists</a> therapy may also be of use.<sup id=\"cite_ref-pmid18068992_7-0\" class=\"reference\"><a href=\"#cite_note-pmid18068992-7\">&#91;7&#93;</a></sup> Some behavioral characteristics may respond to <a href=\"/wiki/Psychotherapy\" title=\"Psychotherapy\">psychotherapy</a>; and <a href=\"/wiki/Social_support\" title=\"Social support\">social support</a> is important to control <a href=\"/wiki/Risk_factor\" title=\"Risk factor\">risk factors</a>. In some cases <a href=\"/wiki/Antipsychotic\" title=\"Antipsychotic\">antipsychotic drugs</a> may also be of use in the presence of psychosis, aggression, gambling or hypersexuality.<sup id=\"cite_ref-pmid15247533_4-7\" class=\"reference\"><a href=\"#cite_note-pmid15247533-4\">&#91;4&#93;</a></sup>\n</p><p>Based upon five case reports,<sup id=\"cite_ref-pmid23007193_8-0\" class=\"reference\"><a href=\"#cite_note-pmid23007193-8\">&#91;8&#93;</a></sup><sup id=\"cite_ref-pmid25093777_9-0\" class=\"reference\"><a href=\"#cite_note-pmid25093777-9\">&#91;9&#93;</a></sup> <a href=\"/wiki/Valproic_acid\" class=\"mw-redirect\" title=\"Valproic acid\">valproic acid</a> may have efficacy in controlling the symptoms of levodopa-induced DDS that arise from the use of levodopa for the treatment of <a href=\"/wiki/Parkinson%27s_disease\" title=\"Parkinson&#39;s disease\">Parkinson's disease</a>.<sup id=\"cite_ref-pmid25114917_10-0\" class=\"reference\"><a href=\"#cite_note-pmid25114917-10\">&#91;10&#93;</a></sup><sup id=\"cite_ref-pmid24288035_11-0\" class=\"reference\"><a href=\"#cite_note-pmid24288035-11\">&#91;11&#93;</a></sup><sup id=\"cite_ref-pmid24313567_12-0\" class=\"reference\"><a href=\"#cite_note-pmid24313567-12\">&#91;12&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Epidemiology\">Epidemiology</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Dopamine_dysregulation_syndrome&amp;action=edit&amp;section=6\" title=\"Edit section: Epidemiology\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>DDS is not common among PD patients. Prevalence may be around 4%.<sup id=\"cite_ref-pmid17988927_1-1\" class=\"reference\"><a href=\"#cite_note-pmid17988927-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-pmid15390130_5-1\" class=\"reference\"><a href=\"#cite_note-pmid15390130-5\">&#91;5&#93;</a></sup> Its prevalence is higher among males with an early onset of the disease.<sup id=\"cite_ref-pmid14505581_2-7\" class=\"reference\"><a href=\"#cite_note-pmid14505581-2\">&#91;2&#93;</a></sup> Previous <a href=\"/wiki/Substance_abuse\" title=\"Substance abuse\">substance abuse</a> such as <a href=\"/wiki/Alcoholism\" title=\"Alcoholism\">heavy drinking</a> or drug intake seems to be the main risk factor along with a history of <a href=\"/wiki/Affective_disorder\" class=\"mw-redirect\" title=\"Affective disorder\">affective disorder</a>.<sup id=\"cite_ref-pmid14505581_2-8\" class=\"reference\"><a href=\"#cite_note-pmid14505581-2\">&#91;2&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"History\">History</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Dopamine_dysregulation_syndrome&amp;action=edit&amp;section=7\" title=\"Edit section: History\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>PD was first formally described in 1817,<sup id=\"cite_ref-pmid11983801_13-0\" class=\"reference\"><a href=\"#cite_note-pmid11983801-13\">&#91;13&#93;</a></sup> however L-dopa did not enter clinical practice until almost 1970.<sup id=\"cite_ref-pmid5637779_14-0\" class=\"reference\"><a href=\"#cite_note-pmid5637779-14\">&#91;14&#93;</a></sup><sup id=\"cite_ref-pmid5820999_15-0\" class=\"reference\"><a href=\"#cite_note-pmid5820999-15\">&#91;15&#93;</a></sup> In these initial works there were already reports of neuropsychiatric complications.<sup id=\"cite_ref-pmid5820999_15-1\" class=\"reference\"><a href=\"#cite_note-pmid5820999-15\">&#91;15&#93;</a></sup> During the following decades cases featuring DDS symptoms in relation to dopamine therapy such as hypersexuality, gambling or <a href=\"/wiki/Punding\" title=\"Punding\">punding</a>, appeared.<sup id=\"cite_ref-pmid10495047_16-0\" class=\"reference\"><a href=\"#cite_note-pmid10495047-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-pmid6685318_17-0\" class=\"reference\"><a href=\"#cite_note-pmid6685318-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-pmid10945141_18-0\" class=\"reference\"><a href=\"#cite_note-pmid10945141-18\">&#91;18&#93;</a></sup> DDS was first described as a syndrome in the year 2000.<sup id=\"cite_ref-pmid10727476_19-0\" class=\"reference\"><a href=\"#cite_note-pmid10727476-19\">&#91;19&#93;</a></sup> Three years later the first review articles on the syndrome were written, showing an increasing awareness of the DDS importance.<sup id=\"cite_ref-pmid17988927_1-2\" class=\"reference\"><a href=\"#cite_note-pmid17988927-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-pmid15247533_4-8\" class=\"reference\"><a href=\"#cite_note-pmid15247533-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-pmid14505581_2-9\" class=\"reference\"><a href=\"#cite_note-pmid14505581-2\">&#91;2&#93;</a></sup> Diagnostic criteria were proposed in 2005.<sup id=\"cite_ref-pmid15390130_5-2\" class=\"reference\"><a href=\"#cite_note-pmid15390130-5\">&#91;5&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Notes\">Notes</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Dopamine_dysregulation_syndrome&amp;action=edit&amp;section=8\" title=\"Edit section: Notes\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-pmid17988927-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid17988927_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid17988927_1-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid17988927_1-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Merims D, Giladi N (2008). \"Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease\". <i>Parkinsonism Relat. Disord</i>. <b>14</b> (4): 273\u201380. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.parkreldis.2007.09.007\">10.1016/j.parkreldis.2007.09.007</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/17988927\">17988927</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Parkinsonism+Relat.+Disord.&amp;rft.atitle=Dopamine+dysregulation+syndrome%2C+addiction+and+behavioral+changes+in+Parkinson%27s+disease&amp;rft.volume=14&amp;rft.issue=4&amp;rft.pages=273-80&amp;rft.date=2008&amp;rft_id=info%3Adoi%2F10.1016%2Fj.parkreldis.2007.09.007&amp;rft_id=info%3Apmid%2F17988927&amp;rft.aulast=Merims&amp;rft.aufirst=D&amp;rft.au=Giladi%2C+N&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADopamine+dysregulation+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid14505581-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid14505581_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid14505581_2-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid14505581_2-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-pmid14505581_2-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-pmid14505581_2-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-pmid14505581_2-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-pmid14505581_2-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-pmid14505581_2-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-pmid14505581_2-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-pmid14505581_2-9\"><sup><i><b>j</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Lawrence AD, Evans AH, Lees AJ (October 2003). <a rel=\"nofollow\" class=\"external text\" href=\"http://linkinghub.elsevier.com/retrieve/pii/S1474442203005295\">\"Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?\"</a>. <i>Lancet Neurol</i>. <b>2</b> (10): 595\u2013604. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/S1474-4422%2803%2900529-5\">10.1016/S1474-4422(03)00529-5</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/14505581\">14505581</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Lancet+Neurol&amp;rft.atitle=Compulsive+use+of+dopamine+replacement+therapy+in+Parkinson%27s+disease%3A+reward+systems+gone+awry%3F&amp;rft.volume=2&amp;rft.issue=10&amp;rft.pages=595-604&amp;rft.date=2003-10&amp;rft_id=info%3Adoi%2F10.1016%2FS1474-4422%2803%2900529-5&amp;rft_id=info%3Apmid%2F14505581&amp;rft.aulast=Lawrence&amp;rft.aufirst=AD&amp;rft.au=Evans%2C+AH&amp;rft.au=Lees%2C+AJ&amp;rft_id=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1474442203005295&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADopamine+dysregulation+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid15935475-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid15935475_3-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Cools R (2006). \"Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease\". <i>Neurosci Biobehav Rev</i>. <b>30</b> (1): 1\u201323. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.neubiorev.2005.03.024\">10.1016/j.neubiorev.2005.03.024</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/15935475\">15935475</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neurosci+Biobehav+Rev&amp;rft.atitle=Dopaminergic+modulation+of+cognitive+function-implications+for+L-DOPA+treatment+in+Parkinson%27s+disease&amp;rft.volume=30&amp;rft.issue=1&amp;rft.pages=1-23&amp;rft.date=2006&amp;rft_id=info%3Adoi%2F10.1016%2Fj.neubiorev.2005.03.024&amp;rft_id=info%3Apmid%2F15935475&amp;rft.au=Cools+R&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADopamine+dysregulation+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid15247533-4\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid15247533_4-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid15247533_4-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid15247533_4-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-pmid15247533_4-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-pmid15247533_4-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-pmid15247533_4-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-pmid15247533_4-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-pmid15247533_4-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-pmid15247533_4-8\"><sup><i><b>i</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Evans AH, Lees AJ (August 2004). <a rel=\"nofollow\" class=\"external text\" href=\"http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1350-7540&amp;volume=17&amp;issue=4&amp;spage=393\">\"Dopamine dysregulation syndrome in Parkinson's disease\"</a>. <i>Curr. Opin. Neurol</i>. <b>17</b> (4): 393\u20138. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1097/01.wco.0000137528.23126.41\">10.1097/01.wco.0000137528.23126.41</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/15247533\">15247533</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Curr.+Opin.+Neurol.&amp;rft.atitle=Dopamine+dysregulation+syndrome+in+Parkinson%27s+disease&amp;rft.volume=17&amp;rft.issue=4&amp;rft.pages=393-8&amp;rft.date=2004-08&amp;rft_id=info%3Adoi%2F10.1097%2F01.wco.0000137528.23126.41&amp;rft_id=info%3Apmid%2F15247533&amp;rft.aulast=Evans&amp;rft.aufirst=AH&amp;rft.au=Lees%2C+AJ&amp;rft_id=http%3A%2F%2Fmeta.wkhealth.com%2Fpt%2Fpt-core%2Ftemplate-journal%2Flwwgateway%2Fmedia%2Flandingpage.htm%3Fissn%3D1350-7540%26volume%3D17%26issue%3D4%26spage%3D393&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADopamine+dysregulation+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid15390130-5\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid15390130_5-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid15390130_5-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid15390130_5-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Pezzella FR, Colosimo C, Vanacore N,  et al. (January 2005). \"Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease\". <i>Mov. Disord</i>. <b>20</b> (1): 77\u201381. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1002/mds.20288\">10.1002/mds.20288</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/15390130\">15390130</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Mov.+Disord.&amp;rft.atitle=Prevalence+and+clinical+features+of+hedonistic+homeostatic+dysregulation+in+Parkinson%27s+disease&amp;rft.volume=20&amp;rft.issue=1&amp;rft.pages=77-81&amp;rft.date=2005-01&amp;rft_id=info%3Adoi%2F10.1002%2Fmds.20288&amp;rft_id=info%3Apmid%2F15390130&amp;rft.aulast=Pezzella&amp;rft.aufirst=FR&amp;rft.au=Colosimo%2C+C&amp;rft.au=Vanacore%2C+N&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADopamine+dysregulation+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid14598089-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid14598089_6-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Pezzella FR, Di Rezze S, Chianese M,  et al. (October 2003). \"Hedonistic homeostatic dysregulation in Parkinson's disease: a short screening questionnaire\". <i>Neurol. Sci</i>. <b>24</b> (3): 205\u20136. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1007/s10072-003-0132-0\">10.1007/s10072-003-0132-0</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/14598089\">14598089</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neurol.+Sci.&amp;rft.atitle=Hedonistic+homeostatic+dysregulation+in+Parkinson%27s+disease%3A+a+short+screening+questionnaire&amp;rft.volume=24&amp;rft.issue=3&amp;rft.pages=205-6&amp;rft.date=2003-10&amp;rft_id=info%3Adoi%2F10.1007%2Fs10072-003-0132-0&amp;rft_id=info%3Apmid%2F14598089&amp;rft.aulast=Pezzella&amp;rft.aufirst=FR&amp;rft.au=Di+Rezze%2C+S&amp;rft.au=Chianese%2C+M&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADopamine+dysregulation+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid18068992-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid18068992_7-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Kimber TE, Thompson PD, Kiley MA (February 2008). \"Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease\". <i><a href=\"/wiki/J_Clin_Neurosci\" class=\"mw-redirect\" title=\"J Clin Neurosci\">J Clin Neurosci</a></i>. <b>15</b> (2): 205\u20138. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.jocn.2006.04.019\">10.1016/j.jocn.2006.04.019</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/18068992\">18068992</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J+Clin+Neurosci&amp;rft.atitle=Resolution+of+dopamine+dysregulation+syndrome+following+cessation+of+dopamine+agonist+therapy+in+Parkinson%27s+disease&amp;rft.volume=15&amp;rft.issue=2&amp;rft.pages=205-8&amp;rft.date=2008-02&amp;rft_id=info%3Adoi%2F10.1016%2Fj.jocn.2006.04.019&amp;rft_id=info%3Apmid%2F18068992&amp;rft.aulast=Kimber&amp;rft.aufirst=TE&amp;rft.au=Thompson%2C+PD&amp;rft.au=Kiley%2C+MA&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADopamine+dysregulation+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid23007193-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid23007193_8-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Sriram A, Ward HE, Hassan A, Iyer S, Foote KD, Rodriguez RL, McFarland NR, Okun MS (February 2013). \"Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease\". <i>Journal of Neurology</i>. <b>260</b> (2): 521\u2013517. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1007/s00415-012-6669-1\">10.1007/s00415-012-6669-1</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/23007193\">23007193</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Neurology&amp;rft.atitle=Valproate+as+a+treatment+for+dopamine+dysregulation+syndrome+%28DDS%29+in+Parkinson%27s+disease&amp;rft.volume=260&amp;rft.issue=2&amp;rft.pages=521-517&amp;rft.date=2013-02&amp;rft_id=info%3Adoi%2F10.1007%2Fs00415-012-6669-1&amp;rft_id=info%3Apmid%2F23007193&amp;rft.aulast=Sriram&amp;rft.aufirst=A&amp;rft.au=Ward%2C+HE&amp;rft.au=Hassan%2C+A&amp;rft.au=Iyer%2C+S&amp;rft.au=Foote%2C+KD&amp;rft.au=Rodriguez%2C+RL&amp;rft.au=McFarland%2C+NR&amp;rft.au=Okun%2C+MS&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADopamine+dysregulation+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid25093777-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid25093777_9-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Epstein J, Madiedo CJ, Lai L, Hayes MT (2014). \"Successful treatment of dopamine dysregulation syndrome with valproic acid\". <i>The Journal of Neuropsychiatry and Clinical Neurosciences</i>. <b>26</b> (3): E3. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1176/appi.neuropsych.13060126\">10.1176/appi.neuropsych.13060126</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/25093777\">25093777</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Journal+of+Neuropsychiatry+and+Clinical+Neurosciences&amp;rft.atitle=Successful+treatment+of+dopamine+dysregulation+syndrome+with+valproic+acid&amp;rft.volume=26&amp;rft.issue=3&amp;rft.pages=E3&amp;rft.date=2014&amp;rft_id=info%3Adoi%2F10.1176%2Fappi.neuropsych.13060126&amp;rft_id=info%3Apmid%2F25093777&amp;rft.aulast=Epstein&amp;rft.aufirst=J&amp;rft.au=Madiedo%2C+CJ&amp;rft.au=Lai%2C+L&amp;rft.au=Hayes%2C+MT&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADopamine+dysregulation+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid25114917-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid25114917_10-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Pirritano D, Plastino M, Bosco D, Gallelli L, Siniscalchi A, De Sarro G (2014). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4119624\">\"Gambling disorder during dopamine replacement treatment in Parkinson's disease: a comprehensive review\"</a>. <i>Biomed Res Int</i>. <b>2014</b>: 728038. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1155/2014/728038\">10.1155/2014/728038</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4119624\">4119624</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/25114917\">25114917</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Biomed+Res+Int&amp;rft.atitle=Gambling+disorder+during+dopamine+replacement+treatment+in+Parkinson%27s+disease%3A+a+comprehensive+review&amp;rft.volume=2014&amp;rft.pages=728038&amp;rft.date=2014&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4119624&amp;rft_id=info%3Apmid%2F25114917&amp;rft_id=info%3Adoi%2F10.1155%2F2014%2F728038&amp;rft.aulast=Pirritano&amp;rft.aufirst=D&amp;rft.au=Plastino%2C+M&amp;rft.au=Bosco%2C+D&amp;rft.au=Gallelli%2C+L&amp;rft.au=Siniscalchi%2C+A&amp;rft.au=De+Sarro%2C+G&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4119624&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADopamine+dysregulation+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid24288035-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid24288035_11-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Connolly B, Fox SH (2014). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3899484\">\"Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease\"</a>. <i>Neurotherapeutics</i>. <b>11</b> (1): 78\u201391. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1007/s13311-013-0238-x\">10.1007/s13311-013-0238-x</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3899484\">3899484</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/24288035\">24288035</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neurotherapeutics&amp;rft.atitle=Treatment+of+cognitive%2C+psychiatric%2C+and+affective+disorders+associated+with+Parkinson%27s+disease&amp;rft.volume=11&amp;rft.issue=1&amp;rft.pages=78-91&amp;rft.date=2014&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3899484&amp;rft_id=info%3Apmid%2F24288035&amp;rft_id=info%3Adoi%2F10.1007%2Fs13311-013-0238-x&amp;rft.aulast=Connolly&amp;rft.aufirst=B&amp;rft.au=Fox%2C+SH&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3899484&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADopamine+dysregulation+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid24313567-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid24313567_12-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Averbeck BB, O'Sullivan SS, Djamshidian A (2014). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4197852\">\"Impulsive and compulsive behaviors in Parkinson's disease\"</a>. <i>Annu Rev Clin Psychol</i>. <b>10</b>: 553\u201380. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1146/annurev-clinpsy-032813-153705\">10.1146/annurev-clinpsy-032813-153705</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4197852\">4197852</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/24313567\">24313567</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annu+Rev+Clin+Psychol&amp;rft.atitle=Impulsive+and+compulsive+behaviors+in+Parkinson%27s+disease&amp;rft.volume=10&amp;rft.pages=553-80&amp;rft.date=2014&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4197852&amp;rft_id=info%3Apmid%2F24313567&amp;rft_id=info%3Adoi%2F10.1146%2Fannurev-clinpsy-032813-153705&amp;rft.aulast=Averbeck&amp;rft.aufirst=BB&amp;rft.au=O%27Sullivan%2C+SS&amp;rft.au=Djamshidian%2C+A&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4197852&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADopamine+dysregulation+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid11983801-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid11983801_13-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Parkinson J (2002). <a rel=\"nofollow\" class=\"external text\" href=\"https://neuro.psychiatryonline.org/doi/pdf/10.1176/jnp.14.2.223\">\"An essay on the shaking palsy\"</a>. <i>J Neuropsychiatry Clin Neurosci</i>. <b>14</b> (2): 223\u201336; discussion 222. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1176/appi.neuropsych.14.2.223\">10.1176/appi.neuropsych.14.2.223</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/11983801\">11983801</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J+Neuropsychiatry+Clin+Neurosci&amp;rft.atitle=An+essay+on+the+shaking+palsy&amp;rft.volume=14&amp;rft.issue=2&amp;rft.pages=223-36%3B+discussion+222&amp;rft.date=2002&amp;rft_id=info%3Adoi%2F10.1176%2Fappi.neuropsych.14.2.223&amp;rft_id=info%3Apmid%2F11983801&amp;rft.au=Parkinson+J&amp;rft_id=https%3A%2F%2Fneuro.psychiatryonline.org%2Fdoi%2Fpdf%2F10.1176%2Fjnp.14.2.223&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADopamine+dysregulation+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid5637779-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid5637779_14-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Cotzias GC (March 1968). \"L-Dopa for Parkinsonism\". <i>N. Engl. J. Med</i>. <b>278</b> (11): 630. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1056/NEJM196803142781127\">10.1056/NEJM196803142781127</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/5637779\">5637779</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.atitle=L-Dopa+for+Parkinsonism&amp;rft.volume=278&amp;rft.issue=11&amp;rft.pages=630&amp;rft.date=1968-03&amp;rft_id=info%3Adoi%2F10.1056%2FNEJM196803142781127&amp;rft_id=info%3Apmid%2F5637779&amp;rft.au=Cotzias+GC&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADopamine+dysregulation+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid5820999-15\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid5820999_15-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid5820999_15-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM (October 1969). \"Treatment of parkinsonism with levodopa\". <i>Arch. Neurol</i>. <b>21</b> (4): 343\u201354. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1001/archneur.1969.00480160015001\">10.1001/archneur.1969.00480160015001</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/5820999\">5820999</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Arch.+Neurol.&amp;rft.atitle=Treatment+of+parkinsonism+with+levodopa&amp;rft.volume=21&amp;rft.issue=4&amp;rft.pages=343-54&amp;rft.date=1969-10&amp;rft_id=info%3Adoi%2F10.1001%2Farchneur.1969.00480160015001&amp;rft_id=info%3Apmid%2F5820999&amp;rft.aulast=Yahr&amp;rft.aufirst=MD&amp;rft.au=Duvoisin%2C+RC&amp;rft.au=Schear%2C+MJ&amp;rft.au=Barrett%2C+RE&amp;rft.au=Hoehn%2C+MM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADopamine+dysregulation+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid10495047-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid10495047_16-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Fernandez HH, Friedman JH (September 1999). \"Punding on L-dopa\". <i>Mov. Disord</i>. <b>14</b> (5): 836\u20138. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1002/1531-8257%28199909%2914%3A5%3C836%3A%3AAID-MDS1018%3E3.0.CO%3B2-0\">10.1002/1531-8257(199909)14:5&#60;836::AID-MDS1018&#62;3.0.CO;2-0</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/10495047\">10495047</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Mov.+Disord.&amp;rft.atitle=Punding+on+L-dopa&amp;rft.volume=14&amp;rft.issue=5&amp;rft.pages=836-8&amp;rft.date=1999-09&amp;rft_id=info%3Adoi%2F10.1002%2F1531-8257%28199909%2914%3A5%3C836%3A%3AAID-MDS1018%3E3.0.CO%3B2-0&amp;rft_id=info%3Apmid%2F10495047&amp;rft.aulast=Fernandez&amp;rft.aufirst=HH&amp;rft.au=Friedman%2C+JH&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADopamine+dysregulation+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid6685318-17\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid6685318_17-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Vogel HP, Schiffter R (July 1983). \"Hypersexuality--a complication of dopaminergic therapy in Parkinson's disease\". <i>Pharmacopsychiatria</i>. <b>16</b> (4): 107\u201310. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1055/s-2007-1017459\">10.1055/s-2007-1017459</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/6685318\">6685318</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pharmacopsychiatria&amp;rft.atitle=Hypersexuality--a+complication+of+dopaminergic+therapy+in+Parkinson%27s+disease&amp;rft.volume=16&amp;rft.issue=4&amp;rft.pages=107-10&amp;rft.date=1983-07&amp;rft_id=info%3Adoi%2F10.1055%2Fs-2007-1017459&amp;rft_id=info%3Apmid%2F6685318&amp;rft.aulast=Vogel&amp;rft.aufirst=HP&amp;rft.au=Schiffter%2C+R&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADopamine+dysregulation+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid10945141-18\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid10945141_18-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Seedat S, Kesler S, Niehaus DJ, Stein DJ (2000). \"Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents\". <i>Depress Anxiety</i>. <b>11</b> (4): 185\u20136. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1002/1520-6394%282000%2911%3A4%3C185%3A%3AAID-DA8%3E3.0.CO%3B2-H\">10.1002/1520-6394(2000)11:4&#60;185::AID-DA8&#62;3.0.CO;2-H</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/10945141\">10945141</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Depress+Anxiety&amp;rft.atitle=Pathological+gambling+behaviour%3A+emergence+secondary+to+treatment+of+Parkinson%27s+disease+with+dopaminergic+agents&amp;rft.volume=11&amp;rft.issue=4&amp;rft.pages=185-6&amp;rft.date=2000&amp;rft_id=info%3Adoi%2F10.1002%2F1520-6394%282000%2911%3A4%3C185%3A%3AAID-DA8%3E3.0.CO%3B2-H&amp;rft_id=info%3Apmid%2F10945141&amp;rft.aulast=Seedat&amp;rft.aufirst=S&amp;rft.au=Kesler%2C+S&amp;rft.au=Niehaus%2C+DJ&amp;rft.au=Stein%2C+DJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADopamine+dysregulation+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid10727476-19\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid10727476_19-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ (April 2000). <a rel=\"nofollow\" class=\"external text\" href=\"http://jnnp.bmj.com/cgi/pmidlookup?view=long&amp;pmid=10727476\">\"Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies\"</a>. <i>J. Neurol. Neurosurg. Psychiatry</i>. <b>68</b> (4): 423\u20138. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1136/jnnp.68.4.423\">10.1136/jnnp.68.4.423</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC1736875\">1736875</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/10727476\">10727476</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J.+Neurol.+Neurosurg.+Psychiatry&amp;rft.atitle=Hedonistic+homeostatic+dysregulation+in+patients+with+Parkinson%27s+disease+on+dopamine+replacement+therapies&amp;rft.volume=68&amp;rft.issue=4&amp;rft.pages=423-8&amp;rft.date=2000-04&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1736875&amp;rft_id=info%3Apmid%2F10727476&amp;rft_id=info%3Adoi%2F10.1136%2Fjnnp.68.4.423&amp;rft.aulast=Giovannoni&amp;rft.aufirst=G&amp;rft.au=O%27Sullivan%2C+JD&amp;rft.au=Turner%2C+K&amp;rft.au=Manson%2C+AJ&amp;rft.au=Lees%2C+AJ&amp;rft_id=http%3A%2F%2Fjnnp.bmj.com%2Fcgi%2Fpmidlookup%3Fview%3Dlong%26pmid%3D10727476&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADopamine+dysregulation+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div>\n\n<!-- \nNewPP limit report\nParsed by mw2183\nCached time: 20180918231948\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.300 seconds\nReal time usage: 0.353 seconds\nPreprocessor visited node count: 1312/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 44876/2097152 bytes\nTemplate argument size: 380/2097152 bytes\nHighest expansion depth: 7/40\nExpensive parser function count: 0/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 34868/5000000 bytes\nNumber of Wikibase entities loaded: 1/400\nLua time usage: 0.162/10.000 seconds\nLua memory usage: 4.82 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  297.611      1 -total\n 58.77%  174.904      1 Template:Reflist\n 46.37%  137.998     19 Template:Cite_journal\n 32.51%   96.758      1 Template:Infobox_medical_condition_(new)\n 28.05%   83.487      1 Template:Infobox\n  1.69%    5.043      3 Template:Main_other\n  0.90%    2.681      1 Template:Template_other\n  0.60%    1.778      1 Template:Column-width\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:20806653-0!canonical and timestamp 20180918231948 and revision id 840774400\n -->\n</div>"},"langlinks":[{"lang":"ar","url":"https://ar.wikipedia.org/wiki/%D9%85%D8%AA%D9%84%D8%A7%D8%B2%D9%85%D8%A9_%D8%AE%D9%84%D9%84_%D8%AA%D9%86%D8%B8%D9%8A%D9%85_%D8%A7%D9%84%D8%AF%D9%88%D8%A8%D8%A7%D9%85%D9%8A%D9%86","langname":"Arabic","autonym":"\u0627\u0644\u0639\u0631\u0628\u064a\u0629","*":"\u0645\u062a\u0644\u0627\u0632\u0645\u0629 \u062e\u0644\u0644 \u062a\u0646\u0638\u064a\u0645 \u0627\u0644\u062f\u0648\u0628\u0627\u0645\u064a\u0646"},{"lang":"bs","url":"https://bs.wikipedia.org/wiki/Sindrom_poreme%C4%87ene_regulacije_dopamina","langname":"Bosnian","autonym":"bosanski","*":"Sindrom poreme\u0107ene regulacije dopamina"},{"lang":"fr","url":"https://fr.wikipedia.org/wiki/Syndrome_de_dysr%C3%A9gulation_dopaminergique","langname":"French","autonym":"fran\u00e7ais","*":"Syndrome de dysr\u00e9gulation dopaminergique"}],"categories":[{"sortkey":"","hidden":"","*":"Infobox_medical_condition_(new)"},{"sortkey":"*","hidden":"","*":"Pages_using_infobox_medical_condition_with_unknown_parameters"},{"sortkey":"","*":"Parkinson's_disease"},{"sortkey":"","*":"Aging-associated_diseases"},{"sortkey":"","*":"Addiction_psychiatry"},{"sortkey":"","*":"Neurological_disorders"},{"sortkey":"","*":"Addiction"},{"sortkey":"","*":"Syndromes"},{"sortkey":"","*":"Dopamine"}],"links":[{"ns":0,"exists":"","*":"Addiction"},{"ns":0,"exists":"","*":"Affective disorder"},{"ns":0,"exists":"","*":"Aggression"},{"ns":0,"exists":"","*":"Alcoholism"},{"ns":0,"exists":"","*":"Antipsychotic"},{"ns":0,"exists":"","*":"Anxiety"},{"ns":0,"exists":"","*":"Apathy"},{"ns":0,"exists":"","*":"Attention"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Dopamine agonist"},{"ns":0,"exists":"","*":"Drug"},{"ns":0,"exists":"","*":"Drug overdose"},{"ns":0,"exists":"","*":"Dysphoria"},{"ns":0,"exists":"","*":"Eating disorder"},{"ns":0,"exists":"","*":"Euphoria (emotion)"},{"ns":0,"exists":"","*":"Executive functions"},{"ns":0,"exists":"","*":"Fatigue (medical)"},{"ns":0,"exists":"","*":"Habituation"},{"ns":0,"exists":"","*":"Hypersexuality"},{"ns":0,"exists":"","*":"Hypomania"},{"ns":0,"exists":"","*":"Impulse control disorder"},{"ns":0,"exists":"","*":"J Clin Neurosci"},{"ns":0,"exists":"","*":"L-Dopa"},{"ns":0,"exists":"","*":"Major depressive disorder"},{"ns":0,"exists":"","*":"Neurology"},{"ns":0,"exists":"","*":"Neuron"},{"ns":0,"exists":"","*":"Oniomania"},{"ns":0,"exists":"","*":"Parkinson's disease"},{"ns":0,"exists":"","*":"Problem gambling"},{"ns":0,"exists":"","*":"Psychosis"},{"ns":0,"exists":"","*":"Psychotherapy"},{"ns":0,"exists":"","*":"PubMed Central"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Punding"},{"ns":0,"exists":"","*":"Putamen"},{"ns":0,"exists":"","*":"Questionnaire"},{"ns":0,"exists":"","*":"Reward system"},{"ns":0,"exists":"","*":"Risk factor"},{"ns":0,"exists":"","*":"Sensitization"},{"ns":0,"exists":"","*":"Sexual addiction"},{"ns":0,"exists":"","*":"Social support"},{"ns":0,"exists":"","*":"Striatum"},{"ns":0,"exists":"","*":"Substance abuse"},{"ns":0,"exists":"","*":"Substance dependence"},{"ns":0,"exists":"","*":"Substantia nigra"},{"ns":0,"exists":"","*":"Valproic acid"}],"templates":[{"ns":10,"exists":"","*":"Template:Infobox medical condition (new)"},{"ns":10,"exists":"","*":"Template:Infobox"},{"ns":10,"exists":"","*":"Template:Template other"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":828,"exists":"","*":"Module:Infobox"},{"ns":828,"exists":"","*":"Module:Navbar"},{"ns":828,"exists":"","*":"Module:InfoboxImage"},{"ns":828,"exists":"","*":"Module:String2"},{"ns":828,"exists":"","*":"Module:WikidataIB/sandbox"},{"ns":828,"exists":"","*":"Module:Complex date"},{"ns":828,"exists":"","*":"Module:I18n/complex date"},{"ns":828,"exists":"","*":"Module:Ordinal"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Roman"},{"ns":828,"exists":"","*":"Module:ISOdate"},{"ns":828,"exists":"","*":"Module:DateI18n"},{"ns":828,"exists":"","*":"Module:I18n/date"},{"ns":828,"exists":"","*":"Module:Calendar"},{"ns":828,"exists":"","*":"Module:I18n"},{"ns":828,"*":"Module:WikidataIB/i18n"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"}],"images":["Lock-green.svg","Dopamine_3D_ball.png","Punding.jpg","Slot_machine.jpg"],"externallinks":["//doi.org/10.1016/j.parkreldis.2007.09.007","//www.ncbi.nlm.nih.gov/pubmed/17988927","http://linkinghub.elsevier.com/retrieve/pii/S1474442203005295","//doi.org/10.1016/S1474-4422(03)00529-5","//www.ncbi.nlm.nih.gov/pubmed/14505581","//doi.org/10.1016/j.neubiorev.2005.03.024","//www.ncbi.nlm.nih.gov/pubmed/15935475","http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1350-7540&volume=17&issue=4&spage=393","//doi.org/10.1097/01.wco.0000137528.23126.41","//www.ncbi.nlm.nih.gov/pubmed/15247533","//doi.org/10.1002/mds.20288","//www.ncbi.nlm.nih.gov/pubmed/15390130","//doi.org/10.1007/s10072-003-0132-0","//www.ncbi.nlm.nih.gov/pubmed/14598089","//doi.org/10.1016/j.jocn.2006.04.019","//www.ncbi.nlm.nih.gov/pubmed/18068992","//doi.org/10.1007/s00415-012-6669-1","//www.ncbi.nlm.nih.gov/pubmed/23007193","//doi.org/10.1176/appi.neuropsych.13060126","//www.ncbi.nlm.nih.gov/pubmed/25093777","//www.ncbi.nlm.nih.gov/pmc/articles/PMC4119624","//doi.org/10.1155/2014/728038","//www.ncbi.nlm.nih.gov/pubmed/25114917","//www.ncbi.nlm.nih.gov/pmc/articles/PMC3899484","//doi.org/10.1007/s13311-013-0238-x","//www.ncbi.nlm.nih.gov/pubmed/24288035","//www.ncbi.nlm.nih.gov/pmc/articles/PMC4197852","//doi.org/10.1146/annurev-clinpsy-032813-153705","//www.ncbi.nlm.nih.gov/pubmed/24313567","https://neuro.psychiatryonline.org/doi/pdf/10.1176/jnp.14.2.223","//doi.org/10.1176/appi.neuropsych.14.2.223","//www.ncbi.nlm.nih.gov/pubmed/11983801","//doi.org/10.1056/NEJM196803142781127","//www.ncbi.nlm.nih.gov/pubmed/5637779","//doi.org/10.1001/archneur.1969.00480160015001","//www.ncbi.nlm.nih.gov/pubmed/5820999","//doi.org/10.1002/1531-8257(199909)14:5%3C836::AID-MDS1018%3E3.0.CO;2-0","//www.ncbi.nlm.nih.gov/pubmed/10495047","//doi.org/10.1055/s-2007-1017459","//www.ncbi.nlm.nih.gov/pubmed/6685318","//doi.org/10.1002/1520-6394(2000)11:4%3C185::AID-DA8%3E3.0.CO;2-H","//www.ncbi.nlm.nih.gov/pubmed/10945141","http://jnnp.bmj.com/cgi/pmidlookup?view=long&pmid=10727476","//doi.org/10.1136/jnnp.68.4.423","//www.ncbi.nlm.nih.gov/pmc/articles/PMC1736875","//www.ncbi.nlm.nih.gov/pubmed/10727476"],"sections":[{"toclevel":1,"level":"2","line":"Signs and symptoms","number":"1","index":"1","fromtitle":"Dopamine_dysregulation_syndrome","byteoffset":1504,"anchor":"Signs_and_symptoms"},{"toclevel":1,"level":"2","line":"Causes","number":"2","index":"2","fromtitle":"Dopamine_dysregulation_syndrome","byteoffset":3101,"anchor":"Causes"},{"toclevel":1,"level":"2","line":"Diagnosis","number":"3","index":"3","fromtitle":"Dopamine_dysregulation_syndrome","byteoffset":6124,"anchor":"Diagnosis"},{"toclevel":1,"level":"2","line":"Prevention","number":"4","index":"4","fromtitle":"Dopamine_dysregulation_syndrome","byteoffset":7474,"anchor":"Prevention"},{"toclevel":1,"level":"2","line":"Management","number":"5","index":"5","fromtitle":"Dopamine_dysregulation_syndrome","byteoffset":7815,"anchor":"Management"},{"toclevel":1,"level":"2","line":"Epidemiology","number":"6","index":"6","fromtitle":"Dopamine_dysregulation_syndrome","byteoffset":11021,"anchor":"Epidemiology"},{"toclevel":1,"level":"2","line":"History","number":"7","index":"7","fromtitle":"Dopamine_dysregulation_syndrome","byteoffset":11438,"anchor":"History"},{"toclevel":1,"level":"2","line":"Notes","number":"8","index":"8","fromtitle":"Dopamine_dysregulation_syndrome","byteoffset":14315,"anchor":"Notes"}],"parsewarnings":[],"displaytitle":"Dopamine dysregulation syndrome","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q3508719"}]}}